Inactive Instrument

ERBA Diagnostics Inc Stock Nyse

Equities

US29490B1017

Medical Equipment, Supplies & Distribution

Inovabio S.r.l., Redix Consulting Limited Liability Company and Kolodziejczyk Waldemar acquired Delta Bialogiclas Srl from ERBA Diagnostics, Inc. for €0.05 million. CI
ERBA Diagnostics, Inc. Appoints Jean Felix Lacroix as Chief Financial Officer and Treasurer, Principal Financial Officer and Principal Accounting Officer CI
ERBA Diagnostics, Inc. announced that it expects to receive $8 million in funding from ERBA Diagnostics Mannheim GmbH CI
ERBA Diagnostics, Inc. announced that it has received $0.75 million in funding from ERBA Diagnostics Mannheim GmbH CI
Erba Diagnostics Inc. Enters into a Promissory Note in Favor of Erba Diagnostics Mannheim GmbH CI
ERBA Diagnostics, Inc. announced that it has received $0.25 million in funding from ERBA Diagnostics Mannheim GmbH CI
ERBA Diagnostics, Inc. Announces Management Changes, Effective August 1, 2017 CI
ERBA Diagnostics, Inc. Announces Board Changes CI
ERBA Diagnostics, Inc. Announces Resignation of Ernesina Scala as Chief Financial Officer CI
Hayden Jeffreys to Resign as Interim Chief Executive Officer and Member of Board of Directors of ERBA Diagnostics, Inc., Effective September 11, 2017 CI
ERBA Diagnostics, Inc. announced that it expects to receive $0.75 million in funding from ERBA Diagnostics Mannheim GmbH CI
ERBA Diagnostics, Inc. Secures Revolving Credit Facility of Up to $5,000,000 from Citibank, N.A CI
ERBA Diagnostics, Inc. Enters into Amended and Restated Promissory Note with Citibank CI
ERBA Diagnostics, Inc. Enters into Promissory Note for an Unsecured Loan of Up to $1,000,000 CI
ERBA Diagnostics, Inc. Announces Management Changes CI
More news
ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company's segments include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. Its tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also designs and manufactures laboratory instruments that perform the tests.
More about the company